Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.
Support Care Cancer. 2023 Jun 20;31(7):401. doi: 10.1007/s00520-023-07884-3.
Metastatic breast cancer (MBC) patients are living longer. However, symptom burden remains a significant issue. Technology-based interventions may assist. The purpose of this study was to test a virtual assistant for addressing symptoms in MBC using the Amazon Echo Show with Alexa.
In this partial crossover randomized trial, the immediate treatment group was exposed to the intervention, called Nurse AMIE (Addressing Metastatic Individuals Everyday) for 6 months. The comparison group was unexposed for the first 3 months and then exposed for 3 months. The randomized controlled trial (RCT) during the first 3 months allowed for the evaluation of intervention effects on symptoms and function. The partial crossover maximized exposure to the intervention for evaluation of feasibility, usability, and satisfaction. RCT outcome data were collected at baseline and 3 months. Feasibility, usability, and satisfaction data were collected throughout the first 3 months of intervention exposure.
Forty-two MBC patients were randomized (1:1). Participants were 53 ± 11 years old and 4 ± 7 years from diagnosis with metastatic disease. No significant effects on psychosocial distress, pain, sleep disturbance, fatigue (vitality), quality of life, or chair stands were noted, despite high levels of acceptability (51%), feasibility (65%), and satisfaction (70%).
A high level of participant acceptability, feasibility, usability, and satisfaction all suggest further research on this platform is warranted. The lack of statistically significant effects on symptoms, quality of life, and function may be the result of small sample size.
NCT04673019 (registration date: December 17, 2020).
转移性乳腺癌（MBC）患者的生存期延长。然而，症状负担仍然是一个重大问题。基于技术的干预措施可能会有所帮助。本研究的目的是使用配备 Alexa 的亚马逊 Echo Show 测试一种用于治疗 MBC 症状的虚拟助手。
在这项部分交叉随机试验中，即时治疗组接受了干预措施，称为 Nurse AMIE（每天处理转移性个体），为期 6 个月。对照组在前 3 个月未暴露于干预措施，然后暴露于干预措施 3 个月。前 3 个月的随机对照试验（RCT）允许评估干预措施对症状和功能的影响。部分交叉最大限度地增加了对干预措施的暴露，以评估可行性、可用性和满意度。RCT 结果数据在基线和 3 个月时收集。在干预暴露的前 3 个月中收集了可行性、可用性和满意度数据。
42 名 MBC 患者被随机分配（1:1）。参与者的年龄为 53±11 岁，从诊断为转移性疾病开始的时间为 4±7 年。尽管接受度高（51%）、可行性（65%）和满意度（70%），但未观察到心理困扰、疼痛、睡眠障碍、疲劳（活力）、生活质量或椅子站立等方面的显著影响。
参与者的高接受度、可行性、可用性和满意度均表明，该平台的进一步研究是合理的。在症状、生活质量和功能方面没有统计学上显著的影响，可能是由于样本量小。
NCT04673019（注册日期：2020 年 12 月 17 日）。
